drugset / Trial / NCT05380713
......SMARTEST Trial......
Phase 2
Completed
30 enrolled
University Health Network, Toronto
Ontario Institute for Cancer Research · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The SMARTEST trial is a phase II non-blinded randomized trial designed to evaluate the benefit of low dose cyclophosphamide in sequential combination with sub-ablative radiation (Arm A) versus sub-ablative radiation alone (Arm B) before surgery as well as the safety and efficacy of consolidation tremelimumab-durvalumab for eligible patients after surgery in both arms.
Timeline
- Start
- 2022-05-03
- Primary completion
- 2025-08-11
- Completion
- 2025-12-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | — | — |
| Subject | Durvalumab | Monoclonal antibody | — | — |
| Subject | Tremelimumab | Monoclonal antibody | — | — |